-
公开(公告)号：EP2252631B1
公开(公告)日：2016-04-13
申请号：EP09763010.7
申请日：2009-03-25
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie S. , HUANG, Ling
CPC分类号： C07K16/28 , C07K16/2803 , C07K2317/24 , C07K2317/56
摘要： Chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
-
22.发明公开DEIMMUNIZED SERUM-BINDING DOMAINS AND THEIR USE FOR EXTENDING SERUM HALF-LIFE 有权ENTIMMUNISIERTE血清结合域及其使用再生精华半衰期
公开(公告)号：EP2714079A2
公开(公告)日：2014-04-09
申请号：EP12789439.2
申请日：2012-05-16
申请人： MacroGenics, Inc.
IPC分类号： A61K39/395
CPC分类号： C07K16/32 , A61P35/00 , C07K14/315 , C07K16/2803 , C07K16/2809 , C07K16/283 , C07K16/2851 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/567 , C07K2317/62 , C07K2317/624 , C07K2317/626 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2319/31 , C07K2319/32 , C07K2319/73
摘要： The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules.
-
公开(公告)号：EP3954703A2
公开(公告)日：2022-02-16
申请号：EP21185550.7
申请日：2015-05-29
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie S. , HUANG, Ling , CHICHILI, Gurunadh Reddy , SHAH, Kalpana , LAM, Chia-Ying, Kao , BURKE, Stephen, James , LIU, Liqin , MOORE, Paul, A. , BONVINI, Ezio , BARAT, Bhaswati
IPC分类号： C07K16/18 , C07K16/28 , C07K16/30 , A61P1/04 , A61P1/16 , A61P5/00 , A61P9/10 , A61P11/00 , A61P13/10 , A61P13/12 , A61P17/00 , A61P19/00 , A61P21/00 , A61P35/02 , A61P35/00 , A61P35/04 , A61P1/18 , A61P13/00 , A61P13/08 , A61P15/00 , A61P25/00
摘要： The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
-
24.发明公开
公开(公告)号：EP3839044A1
公开(公告)日：2021-06-23
申请号：EP20217972.7
申请日：2014-03-13
申请人： MacroGenics, Inc. , Duke University
发明人： KOENIG, Scott , JOHNSON, Leslie S. , LAM, Chia-Ying Kao , LIU, Liqin , NORDSTROM, Jeffrey Lee , HAYNES, Barton F. , FERRARI, Guido
IPC分类号： C12N5/16 , A61K39/12 , A61K45/00 , A61K39/00 , A61K39/38 , A01N65/00 , C12N7/00 , C12N7/01 , C12N5/07 , C07K16/10
摘要： The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.
-
25.发明公开
公开(公告)号：EP3808776A1
公开(公告)日：2021-04-21
申请号：EP20206324.4
申请日：2014-08-20
申请人： MacroGenics, Inc.
发明人： BONVINI, Ezio , JOHNSON, Leslie S. , MOORE, Paul A. , CHICHILI, Gurunadh Reddy , ALDERSON, Ralph Froman , HUANG, Ling
IPC分类号： C07K16/28 , C07K16/32 , A61K39/395 , A61K39/00 , A61P11/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/08 , A61P17/02
摘要： The present invention is directed to sequence-optimized CD123 x CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
-
26.发明授权
公开(公告)号：EP3035956B1
公开(公告)日：2020-07-22
申请号：EP14837376.4
申请日：2014-08-20
申请人： MacroGenics, Inc.
-
27.发明授权DEIMMUNIZED SERUM-BINDING DOMAINS AND THEIR USE FOR EXTENDING SERUM HALF-LIFE 有权ENTIMMUNISIERTE血清结合域及其使用再生精华半衰期
公开(公告)号：EP2714079B1
公开(公告)日：2016-09-14
申请号：EP12789439.2
申请日：2012-05-16
申请人： MacroGenics, Inc.
IPC分类号： A61K39/395 , C07K16/28 , C07K16/32 , C07K16/44
CPC分类号： C07K16/32 , A61P35/00 , C07K14/315 , C07K16/2803 , C07K16/2809 , C07K16/283 , C07K16/2851 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/567 , C07K2317/62 , C07K2317/624 , C07K2317/626 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2319/31 , C07K2319/32 , C07K2319/73
摘要： The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules.
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.038 秒)
